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ABSTRACT 
Meagen Kathleen Voss- Characterization of recombinant mouse ecto-5’-
nucleotidase 
(Under the Direction of Mark. J. Zylka, PhD) 
 
 Chronic pain is the most common medical complaint in the United States and 
the number of Americans affected by chronic pain is growing.  Effectiveness of 
available treatments varies greatly and many have intolerable side effects.  To 
address this need for pain treatments, more effective therapies are needed.  
Recently, our lab discovered an ectonucleotidase in the central nervous system 
(CNS) called Prostatic Acid Phosphatase (PAP).  Spinal injections of PAP into live 
mice produced antinociceptive effects.  The following thesis describes the properties 
of NT5E, an ectonucleotidase that is colocalized with PAP in the CNS.  We have 
generated a recombinant mouse NT5E protein (mNT5E) and have shown that the 
protein is pure, catalytically active and capable of reducing nociceptive sensitivity in 
two animal models of chronic pain.  We also show that mNT5E acts through A1-type 
adenosine receptors (A1R).  This study provides an additional target for developing 
pain treatments and a new tool for studying purinergic signaling.
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CHAPTER ONE 
BACKGROUND AND SIGNIFICANCE 
 
1-1 Chronic Pain: A Growing National Problem 
Pain is the number one health care problem faced by modern medicine.  
According to the American Pain Foundation, more Americans suffer from chronic 
pain than heart disease, cancer and diabetes combined (Foundation, 2009).  
Despite the high incidence of these conditions, patients suffering from chronic pain 
are vastly undertreated.  Part of this trend can be ascribed to treatment bias on the 
part of medical professionals.  At the same time, there is an understandable restraint 
in prescribing potent analgesics.  Many of these drugs are accompanied by 
detrimental side effects that severely affect patients’ quality of life.  Addiction to 
analgesic medications, in particular, is a significant problem that is difficult to treat.  
Most potent analgesics will also only provide short term relief as many patients 
develop a tolerance to them over time. 
This lack of effective treatments for chronic pain is a critical national health 
problem that severely impacts productivity in the workplace and continues to deplete 
vital financial resources.  According to a study conducted by the National Institutes 
of Health, chronic pain treatment has an estimated cost of $100 billion per year, 
including cost of treatment, lost income and lost productivity (NIH, 1998).  A more 
recent survey conducted by Harris Interactive and the National Pain Foundation in 
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2006 revealed that persistent chronic pain has increased by 40% in the workplace, 
suggesting that the incidence of pain will continue to grow unless effective 
treatments are implemented. 
In answer to this disturbing trend, we and other scientists are investigating the 
molecular roots of pain; hoping that by understanding more about the pain process 
itself, we can develop more effective treatments.  Our specific focus is on molecules 
that are involved in endogenous pain mechanisms that can potentially be 
manipulated to relieve pain.  The following dissertation describes how we uncovered 
one of these molecules—ecto-5’-nucleotidase (NT5E)—through a powerful 
combination of molecular genetics and behavioral neuroscience.  We hope that 
NT5E, and other molecules we uncover in the future, will lead to new treatments to 
help curb this burgeoning epidemic of pain. 
 
1-2 How the Body Senses Pain: The Nociceptive Nervous System 
Strictly defined, pain is “an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or described in terms of such 
damage (Taxonomy, 1994)”.  Since emotional experience cannot be interpreted 
beyond reasonable doubt in animals, pain is a phenomenon that is unique to 
humans.  Nevertheless, all mammals, as well as many invertebrates, possess 
nervous systems that are capable of detecting noxious stimuli through a process 
called nociception.   
Nociception is an integral part of the nervous system.  The mammalian body 
constantly interprets the outside world through the web of nerve fibers that constitute 
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the peripheral nervous system.  Every single moment, these fibers are detecting, 
integrating and conveying somatosensory information to the brain, which then 
interprets the collected “data”.  These fibers are either specialized to detect a 
specific type of stimuli or have the capactity to sense multiple types of stimuli.   In 
the skin, there are specialized fibers for detecting heat, cold, harmful chemicals, 
pressure and vibration (Julius and Basbaum, 2001; Meyer et al., 2006).  Nociception 
is mediated by nociceptors.  This special class of neurons is activated by chemical 
irritants, noxious heat, and potentially harmful pressure, but they are not activated by 
innocuous stimuli like gentle touch (Burgess and Perl, 1967).   
Nociceptors can be divided into different classes based on their 
eletrophysiological response to certain stimuli (See Figure 1.1).  Medium diameter 
nociceptors with thinly myelinated axons are known as Aδ fibers.  These fibers 
conduct action potentials very rapidly (though not as rapidly as Aβ fibers— a class of 
sensory neurons which detect innocuous stimuli).  Evidence from previous studies 
suggests that these fibers are responsible for pricking, sharp pain as well as the 
detection of noxious heat and sensitization following a burn or chemical injury 
(Campbell et al., 1979; Julius and Basbaum, 2001; Ringkamp et al., 2001; Treede et 
al., 1998).  Unlike the rapid response of Aδ fibers, nociceptors with the smallest 
diameters conduct action potentials very slowly due to their unmyelinated axons.  
Called C-fiber nociceptors, these cells are thought to be responsible for burning pain 
sensations (Julius and Basbaum, 2001; Meyer et al., 2006).  Polymodal, they 
respond to noxious thermal, chemical and mechanical stimuli.  With their slow 
adapting responses to chemical and mechanical stimuli, they have also been 
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implicated in hyperalgesia, a type of sensitization that occurs following tissue injury 
(Peng et al., 2003). 
 The cell bodies of nociceptors reside within the trigeminal and dorsal root 
ganglia (DRG) that flank the brain stem and spinal cord, respectively.  Nociceptors 
have a pseudo-unipolar morphology with a long axon that bifurcates into two distinct 
processes (Meyer et al., 2006).  The distal fibers travel out of the ganglia to 
innervate various parts of the body while the proximal processes connect to the 
central nervous system through synapses in the spinal cord or brainstem.  This 
junction between nociceptors and neurons that ascend to the brain is where critical 
information transmission occurs in nociception (See Figure 1.2).  As such, this 
junction presents an ideal target for the development of prophylactic pain treatments.  
Yet, it is only recently that researchers have begun to grasp the complexity of this 
intricate sensory system. 
 
1-3 Classifying nociceptors based on molecular markers 
 In addition to their size and electrophysiological properties, nociceptors can 
also be distinguished based on the expression of molecular markers.  The functions 
of these proteins are varied. They include cell surface proteins, stored peptides, 
secreted molecules and a number of enzymes (Meyer et al., 2006).  While the 
distribution of markers is not necessarily conserved across species and fluctuates in 
response to injury, these markers are useful for dividing nociceptors into specific 
subclasses (Meyer et al., 2006; Zwick et al., 2002).  Recent studies have taken 
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advantage of these markers to categorize these neurons into distinct nociceptive 
circuits based on anatomy and functionality (Cavanaugh et al., 2009; Zylka et al., 
2005).  Large diameter neurons with Aβ and Aδ fibers can be identified with the 
molecular marker neurofilament protein NF200 (Meyer et al., 2006). 
 In the DRG, small diameter neurons are roughly divided into two classes 
based on molecular markers: peptidergic and nonpeptidergic (See Figure 1.3) 
(Julius and Basbaum, 2001; Meyer et al., 2006; Zylka et al., 2005).  Peptidergic 
neurons contain peptide markers like substance P, calcitonin gene-related peptide 
(CGRP), somatostatin, the capsaicin receptor TRPV1 and TrkA (Fitzgerald, 2005; 
Meyer et al., 2006).  Roughly 40% of small diameter DRG neurons have been 
classified as peptidergic (Lawson et al., 1996; McCarthy and Lawson, 1989).  In 
addition to these unique markers, peptidergic neurons also project to laminae I and 
IIouter of the dorsal horn in the spinal cord (Hunt and Mantyh, 2001; Ribeiro et al., 
2003; Zylka et al., 2005) 
Nonpeptidergic neurons are able to bind the plant lectin IB4.  They are also 
distinguished by expression of the ATP gated ion channel P2X3 and prostatic acid 
phosphatase (PAP, also known as FRAP), an enzyme that has been shown to be 
antinociceptive in mice (Zylka et al., 2008).  It should be noted that there is some 
overlap between PAP and peptidergic markers like substance P and CGRP.  PAP 
expression, in particular, has been found in both peptidergic and nonpeptidergic 
neurons.  However, nonpeptidergic neurons can ultimately be identified because 
they specifically innervate lamina II of the dorsal horn (Perry and Lawson, 1998; 
Zylka et al., 2005). 
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Though there is some overlap between these two categories of nociceptive 
neurons, this classification system continues to be useful for defining nociceptors.   
The segregation of specific proteins in peptidergic versus nonpeptidergic neurons as 
well as the strict division of their axon terminals in the dorsal horn suggests that 
there are conserved functions for each class of neurons (Zylka et al., 2005).  
Continued exploration of these protein markers will ultimately help researchers 
determine the functional differences between these nociceptor classes and 
contribute to a better understanding nociception as a whole. 
 
1-4 Purinergic Signaling in Nociception 
 Purinergic signaling between cells facilitates a number of critical functions 
which include endocrine secretion, immune response, inflammation, vasodilatation, 
cell proliferation, cell death and nociception (Burnstock, 2007; Burnstock, 2009).  
The first mention of the potent extracellular signaling actions of adenine molecules 
appeared in a seminal paper by Drury and Szent-Gyorgyi in 1929 (Drury and Szent-
Györgyi, 1929).  The concept of adenine molecule signaling was initially resisted due 
to the well-established intracellular roles of adenosine triphosphate (ATP)—
particularly its role in metabolism.  Burnstock later characterized the process further 
and coined the term “purinergic” signaling in his 1972 review.  In the years following 
his pivotal review, Burnstock further postulated the existence of purinergic receptors 
and categorized them into two distinct families of nucleoside-activated and 
nucleotide-activated receptors (Burnstock, 1976; Burnstock, 1978).  Around the 
same time, other studies hinted that ATP could be a pronociceptive compound.  But 
 7 
 
it took more time for researchers to establish a connection between purinergic 
receptors and nociception. 
 
1-4.1 The pronociceptive properties of ATP 
 The first hint that ATP was a pronociceptive agent occurred when Keele and 
Collier washed broken blisters on human skin with an ATP solution in 1964.  At the 
time, the blister base preparation—where blisters are induced then ruptured to 
“expose” aggravated nerve endings—was one of the best methods available to 
compare the pain-inducing properties of different compounds.  Keele and Collier 
observed that their subjects recorded higher pain scores when the exposed blisters 
were treated with ATP.  Keele replicated his results with Bleehen a decade later.  In 
the mean time, Collier et al. had established that ATP is pronociceptive in mice.  
Following these seminal studies, other groups found evidence that the 
electrophysiological response of nociceptors to ATP was substantially different from 
nonnociceptive neurons.  Despite this progress, the molecular mechanism for ATP 
stimulated nociception remained unclear. 
 
 1-4.2 P2X and P2Y Receptors 
 Following the discovery of purinergic receptors in 1972, the receptors were 
divided into two groups: one for adenosine activated receptors (P1) and another for 
ATP/ADP activated receptors (P2).  Later on, the P2 receptors were further 
segregated into a class of ion-gated receptors (P2X) and a class of G protein-
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coupled receptors (P2Y).  Most of these receptors are conserved across mammalian 
species and to date twenty-seven purinergic receptors have been identified. 
There are fifteen known P2 receptors.  Seven are P2X subunits that combine 
with each other to form trimeric cation channels permeable to Na+ and Ca2+ 
(Sawynok, 2007).  The other eight are P2Y receptors; mebatropic G protein-coupled 
receptors that activate various signaling pathways.  Though both receptor subtypes 
are activated by ATP and ADP, P2Y receptors can also be activated by pyrimidine 
and purine nucleosides (Burnstock, 2009).  Three P2Y receptors also favor 
diphosphate substrates like ADP.  These differences in substrate specificity and 
preference suggest P2X and P2Y receptors have different regulatory roles.  But how 
are those roles linked to nociception? 
 The first major connection between nociception and purinergic signaling was 
made in 1995 when the P2X3 ionotropic receptor was cloned by two separate groups 
(Chen et al., 1995; Lewis et al., 1995).  The receptor was predominantly localized to 
small diameter nociceptive neurons in the DRG along with the heteromultimer 
channel P2X2/3.  Both groups of investigators demonstrated that the neurons could 
be activated by ATP in vitro.  Years later, Jarvis, et al. demonstrated that P2X3 
agonists produced an increase in nociceptive behavior in vivo (Jarvis and Kowaluk, 
2001).  Jarvis, et al. also showed that the converse was true: they found that 
subcutaneous injections of A-317491, a specific P2X3 antagonist, reduced 
nociceptive behaviors in rats.  Knockdown of P2X3 using antisense oligonucleotides 
also reduced nociceptive behaviors in different models of induced hyperalgesia 
(Dorn et al., 2004; Honore et al., 2002).   Further study has uncovered roles for 
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these receptors in many different pain modalities including neuropathic, 
inflammatory, visceral and migraine pain (Wirkner et al., 2007).  Yet, these results 
are complicated by the fact that P2X3 knockout mice show normal sensitivity to 
noxious stimuli in behavioral tests.   However, these mice do display differences in 
sensitivity once an injury has been induced, suggesting that a form of compensation 
is occurring before injury.  Whether compensation occurs during development or 
there is increased function of another P2X receptor subtype has yet to be 
determined. 
 Once the connection between P2X3 and nociception was firmly established, 
researchers began to investigate how other P2X receptors affected nociception.  To 
date, three out of seven P2X receptors have been implicated in nociception: P2X3, 
P2X4 and P2X7.  P2X4 receptors were found in dorsal horn neurons as well is in 
spinal microglia.  A recent study showed that knockdown of P2X4 receptors in rats 
suppressed the development of allodynia following nerve injury (Tsuda et al., 2003).  
This group also showed that administering antagonists of P2X4 receptors also 
reduced tactile allodynia in vivo.  Similar to P2X3, suppressing receptor function with 
a drug produces different results than genetic ablation of the receptor.  P2X4 null 
mice have normal responses in several nociceptive assays, yet they show different 
sensitivity following injury (Tsuda et al., 2009).  P2X7 receptors are also found on 
microglia.  Antagonists for P2X7 receptors reduce nociception in animal models of 
neuropathic pain, yet once again the P2X7-/- mice demonstrate normal nociceptive 
behaviors (Honore et al., 2006; Nelson et al., 2006).  Furthermore, the P2X7-/- 
animals cannot develop inflammatory or neuropathic pain states (Chessell et al., 
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2005).  Despite the puzzling situation involving genetic ablation of P2X receptors, 
these studies nevertheless highlight the importance of P2X receptors in nociception. 
 Four out of eight known P2Y receptors have possible connections to 
nociception:  P2Y1, P2Y2, P2Y4 and P2Y6.  All four receptors were detected in the 
spinal cord.  P2Y2 and P2Y4 were also found in the DRG (Okada et al., 2002).  
Another study refutes this finding by showing only P2Y1 and P2Y2 are in the DRG 
(Kobayashi et al., 2006).  Despite this minor controversy, the role of P2Y receptors 
in nociception was investigated in rodents.  In order to avoid simultaneous activation 
of P2X receptors, many researchers took advantage of the fact that P2Y receptors 
could be activated by pyrimidine as well as purine based substrates.  Most groups 
used either uridine 5’-triphosphate (UTP) or uridine 5’-diphosphate (UDP).  Using 
these substrates, researchers found that P2Y receptors were involved in neuropathic 
pain; receptor activation relieved the allodynia produced by sciatic nerve injury 
(Okada et al., 2002).  Furthermore, intrathecal injection of UTP and UDP increased 
the threshold of naïve animals in testing for mechanical nociception (Okada et al., 
2002).  Pinpointing which receptor is ultimately responsible for these antinociceptive 
effects as specific antagonists for P2Y receptors have yet to be developed.  Since it 
is known that P2Y2 and P2Y4 have an affinity for UTP while P2Y6 has an affinity for 
UDP, most authors suggest that the antinociceptive effect must be mediated by one 
of these three receptors.  Also, P2Y2 has recently been connected to thermal 
nociception and the thermosensor TRPV1 (Malin et al., 2008). 
 Another angle that investigators are beginning to explore is the interaction 
between different P2X and P2Y receptors.  A recent study by Chen, et al. 
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demonstrated that P2X7 receptors in microglial satellite cells exert inhibitory control 
over P2X3 and P2Y1 receptor activity in neurons (Chen et al., 2008).  Though these 
results have yet to be supported by evidence from other groups, the conclusions of 
Chen, et al. reinforce the importance of P2 receptor signaling in nociception and also 
highlight the importance of investigating receptor interaction. 
 
1-4.3 The antinociceptive properties of adenosine 
 While ATP stimulates nociception, adenosine produces the opposite effect.  
The first antinociceptive effect of adenosine was observed by Vapaatalo, et al. in 
1975 when they systemically treated rats with the adenosine analog phenyliso-
propyl-adenosine.  The effect was confirmed by other studies in which drugs were 
administered systemically or delivered directly to the nervous system (Holmgren et 
al., 1983; Yarbrough and McGuffin-Clineschmidt, 1981).  A key advancement in the 
field was made when two separate groups determined that the antinociceptive effect 
of adenosine was occurring through a spinal site (Holmgren et al., 1986; Post, 
1984).  Given that two subtypes of adenosine activated purinergic receptors were 
localized to the spinal cord (Choca et al., 1987; Geiger et al., 1984; Goodman and 
Synder, 1982), the investigators hypothesized that the antinociceptive effects were 
mediated by adenosine receptors. 
 
 1-4.4 Adenosine Receptors 
 When Burnstock postulated the existence of adenosine receptors in 1976, the 
concept of adenosine as a signaling molecule was hardly new.  Since the initial 
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discovery by Drury and Szent-Gyorgyi that showed adenine-containing compounds 
had profound effects on the mammalian heart, numerous other studies have also 
shown that adenosine as well as adenosine analogs can affect many different bodily 
functions (Barsoum and Gaddum, 1935; Cobbin et al., 1974; Drury, 1936; Drury and 
Szent-Györgyi, 1929; Stafford, 1966).  Burnstock initially named the receptors “P1” 
receptors in line with his naming of the “P2” receptors.  This nomenclature was later 
abandoned in favor of terminology that described the endogenous agonist of the 
receptors (Fredholm et al., 2001).  Currently, there are four known adenosine 
receptors: A1, A2A, A2B and A3.  All adenosine receptors are G protein-coupled, 
seven transmembrane domain receptors. 
Of the four known adenosine receptors, the A1 adenosine receptor (A1R) is 
the most firmly connected to nociception.  A1R in the nervous system is expressed in 
DRG, trigeminal ganglion neurons and throughout the spinal cord (Carruthers et al., 
2001; Reppert, et al.,1991; Schulte et al., 2003).  In vitro studies have shown that 
activation of A1R decreases the release of the inflammatory substances CGRP and 
substance P (Sjolund et al., 1997).  Corresponding in vivo studies demonstrated that 
adenosine and adenosine analogs lead to antinociceptive effects through the 
activation of A1R (Aley et al., 1995; Aumeerally et al., 2004; Karlsten et al., 1992; XJ 
and Sawynok, 2001).  Spinal and peripheral delivery of A1R agonists lead to similar 
antinociceptive effects (Dickenson et al., 2000; Sawynok, 1998).  Investigators have 
also successfully activated A1R by manipulating the levels of endogenous 
adenosine; specifically, inhibitors of adenosine kinase and adenosine deaminase 
were antinociceptive in models of inflammatory and neuropathic pain (Jarvis et al., 
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2002a; Kowaluk and Jarvis, 2000; McGaraughty et al., 2001; McGaraughty et al., 
2005).  Generation of A1R knockout mice further confirmed the importance of this 
receptor in nociception.  A1R -/- mice have enhanced thermal sensitivity in the tail flick 
assay and develop enhanced thermal sensitivity following inflammation or nerve 
injury (Johansson et al., 2001; Wu et al., 2005).  Though these animals have normal 
responses to mechanical stimuli at baseline and following injury, they do not respond 
as well to conventional pain treatments like morphine (Wu et al., 2005).  Ultimately, 
these data suggest a key role for A1R in regulating thermal nociception as well as 
participating in the mechanism of morphine analgesia. 
 Unlike A1R, A2A, A2B and A3 receptors are considered to be pronociceptive.  
A2AR is expressed in DRG neurons, glial cells and in the spinal cord (Bura et al., 
2008; Cunha et al., 2006; Haskó et al., 2005; Hussey et al., 2007; Kaelin-Lang et al., 
1998).  Studies have consistently shown that activation of A2AR in the peripheral 
nervous system leads to increased nociceptive behaviors in animals, whereas 
suppression of A2AR activity has led to a reduction in nociceptive behaviors (Doak 
and Sawynok, 1995; Khasar et al., 1995; Taiwo and Levine, 1990).  Yet, the effect of 
A2AR activation in the central nervous system remains unclear.  Both A2AR agonists 
and antagonists lead to antinociception when injected into the spinal cord (Godfrey 
et al., 2006; Hussey et al., 2007; Loram et al., 2009; Regaya et al., 2004; Yoon et 
al., 2005).  The A2AR knockout mice show reduced nociceptive responses to thermal 
tests, decreased thermal hyperalgesia and mechanical allodynia as well a reduced 
response to formalin and opioids (Bura et al., 2008; Godfrey et al., 2006; Ledent et 
al., 1997).  As such, the overall effect of A2AR on nociception is unclear.  A2BRs and 
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A3Rs are located in mast cells in the peripheral nervous system.  Activation of both 
these receptor subtypes leads to the release of inflammatory substances like 
histamine and serotonin.  The knockout mice for both receptors show largely normal 
responses in nociceptive tests except for one report of A3R knockout mice 
demonstrating reduced thermal nociception in the hot plate test.  Ultimately, further 
study is needed of all these receptor subtypes to pinpoint their specific roles in 
nociception. 
 
 1-4.5 Sources of Endogenous Adenosine 
 The fact that adenosine receptor activity is so critical to nociceptive signaling 
in both the peripheral and central nervous systems implies that there are 
endogenous mechanisms for generating adenosine.  Though the precise amount of 
adenosine in the spinal cord is unclear, basal adenosine levels in other locations of 
the CNS are enough to activate high affinity adenosine receptors such as A1 or A2A 
(Dunwiddie and Masino, 2001).  This activation implies that adenosine signaling is a 
constitutive process in the CNS.  As such, injury or other pathologies likely stimulate 
the generation of additional adenosine.  Production of this adenosine occurs 
primarily through two different mechanisms in the spinal cord: intracellular release 
from neurons or the dephosphorylation of released adenosine nucleotides (See 
Figure 1.4). 
 Intracellular ATP is abundant and is a key source of adenosine (Sawynok and 
Liu, 2003).  The enzyme ATPase breaks ATP down into AMP.  Then an enzyme 
called intracellular 5’-nucleotidase ((cN)-I) hydrolyzes AMP into adenosine.  
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Adenosine can also be generated from the metabolism of cAMP our from the 
compound S-adenosyl-homocysteine (SAH) (Latini and Pedata, 2001).  Cells can 
then release adenosine into the extracellular space through equilibrative nucleoside 
transporters or generate inosine for other signaling purposes.  Adenosine release 
can be stimulated in response to compounds associated with injury and 
inflammation, including capsaicin and substance P (Cahill et al., 1997; Sweeney et 
al., 1989).  Release can also occur in response to analgesic drugs such as morphine 
(Sandner-Kiesling et al., 2001; Sweeney et al., 1987a; Sweeney et al., 1987b).  
NMDA, potassium and serotonin have been shown to trigger adenosine release as 
well (Conway et al., 1997; Sweeney et al., 1987a; Sweeney et al., 1989). 
 The other method of generating adenosine in the extracellular space is 
enzyme-mediated dephosphorylation of adenine-containing nucleotides released 
from synaptic vesicles.  ATP is a neurotransmitter and neuromodulator that can act 
specifically on P2X and P2Y receptors (Dunwiddie and Masino, 2001).  In order to 
minimize action of these receptors, ATP is quickly dephosphorylated by enzymes 
called ectonucleotidases.  These enzymes form a “purinergic cascade” in which ATP 
is ultimately broken down into adenosine.  From that point, adenosine can either act 
on adenosine receptors, be taken back up into cells or be converted into inosine.  
Adenosine that enters cells can either be phosphorylated into AMP by adenosine 
kinase or deaminated into inosine by adenosine deaminase.  Blocking the activity of 
these intracellular enzymes has been shown to increase adenosine release, leading 
to antinociceptive effects in vivo (Latini and Pedata, 2001).  But more importantly, 
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the manipulation of extracellular ectonucleotidases leads to profound effects on 
nociception. 
  
1-5 Ectonucleotidases in Nociception 
 Ectonuleotidases are a class of nucleotide-metabolizing enzymes that are 
found on the plasma membrane of cells.  They are distributed throughout the body 
and perform multiple regulatory functions in various tissues (for a comprehensive 
review, see (Yegutkin, 2008)).  As mentioned in section 1-4-5, these enzymes are 
largely responsible for dephosphorylation of ATP to adenosine.  As such, they have 
a key role in the regulation of purinergic receptor activity.  The nervous system 
contains members from all the ectonucleotidase families: ectonucleoside 
triphosphate diphosphohydrolases (ENTPD), ectonucleotide 
pyrophosphatase/phosphodiesterases (ENPP), alkaline phosphatases (AP), acid 
phosphatases and 5’-nucleotidases (Zimmermann, 2006).  Of these various 
enzymes, two have been firmly connected to nociception: an acid phosphatase 
called prostatic acid phosphatase (PAP) and a 5’nucleotidase called ecto-5’-
nucleotidase (NT5E). 
 
1-5.1 Prostatic Acid Phosphatase 
 Early histochemical studies determined that there was an enzyme located in 
lamina II of the spinal cord and specific neurons of the DRG that could 
dephosphorylate thiamine monophosphate (TMP).  Initially named fluoride resistant 
acid phosphatase (FRAP) or TMPase, numerous groups studied the enzyme during 
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the 1970s and the1980s, but were unable to determine what gene  encoded the 
enzyme (Dodd et al., 1983; Sanyal and Rustioni, 1974; Silverman and Kruger, 
1988a).  Many investigations noted that TMPase was localized to small diameter 
nonpeptidergic DRG neurons, suggesting that there was a connection between 
TMPase and nociception.  A few groups even showed that TMPase expression was 
reduced or eliminated when peripheral nerves were damaged (Shields et al., 2003a; 
Tenser, 1985; Tenser et al., 1991).  Upon discovery of another, easier to use, 
marker for nonpeptidergic neurons called isolectin B4(IB4), many investigators 
dropped their pursuit of this elusive enzyme (Silverman and Kruger, 1988b, 1990). 
 Dodd, et al. made the most ambitious attempt to identify the gene when they 
purified TMPase from rat DRGs.  They found that the protein could be inhibited by 
the nonselective acid phosphatase inhibitor, L(+)-tartrate and the protein was similar 
in size to a secretory human protein found in the prostate—prostatic acid 
phosphatase(PAP).  At the time, however, a decent PAP antibody was not available 
and the one used by Dodd, et al. failed to stain the small diameter nociceptive 
neurons where TMPase was located.  As such, they were unable to provide 
conclusive evidence that TMPase was PAP. 
 Decades later, our lab revisited this mystery.  With in situ hybridization we 
showed that small diameter nociceptive neurons specifically express a 
transmembrane isoform of the PAP enzyme; thereby explaining why the protein 
Dodd et al. obtained was larger than the secretory form.  TMP lead histochemistry 
and immunohistochemistry confirmed that PAP was expressed in the DRG and also 
showed that the enzyme was expressed in lamina II of the dorsal horn (Zylka et al., 
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2008).  Additional characterization using molecular markers for peptidergic and 
nonpeptidergic neurons showed that PAP was primarily expressed in nonpeptidergic 
neurons, just like TMPase.  But the most convincing evidence that TMPase was 
PAP arose when these procedures were repeated in PAP-/- mice—the staining in 
the DRG and dorsal horn was completely eliminated (See Figure 1.5). 
 In addition to identifying this mysterious CNS enzyme, our lab also discovered 
that secreted PAP protein has antinociceptive properties.  When injected 
intrathecally (i.t.) in mice, PAP protein profoundly increased pawwithdrawal latency 
to noxious thermal stimuli in naïve mice (Sowa et al., 2009; Zylka et al., 2008).  This 
effect lasted for up to three days and was dose-dependent.  When compared to the 
traditional opioid analgesic morphine, PAP’s analgesic effect lasted eight times 
longer with no observable side effects.  PAP was also antinoceptive in two models of 
chronic pain: the complete Freund’s adjuvant (CFA) model of inflammatory pain and 
the spared nerve injury (SNI) model of neuropathic pain.  Additional behavioral tests 
in PAP-/- mice revealed that the animals had enhanced nociceptive responses 
following injury or inflammation.  This phenotype was rescued when PAP-/- mice 
were injected i.t. with PAP protein. 
 PAP’s ability to function as an ectonucleotidase led us to suspect that the 
enzyme could be connected to the antinoceptive activity of A1 adenosine receptors.  
The selective A1R agonist N6-cyclopentyladenosine (CPA) produced similar, though 
not as long-lasting, antinociceptive effects in our behavioral tests (Zylka et al., 2008).  
Using lead histochemistry and HPLC we demonstrated that PAP was capable of 
dephosphorylating AMP into adenosine in vitro (See Figure 1.6).  Behavioral testing 
 19 
 
using A1R-/- mice further showed that PAP injections were ineffective in the knockout 
animals.  Whereas the wildtype mice displayed decreased sensitivity, the A1R-/- mice 
remained highly sensitive to nociceptive stimuli throughout the testing period.  
Similar results were obtained when the A1R-/- animals were tested in the CFA and 
SNI models.  These tests definitively confirmed that PAP’s antinociception was being 
mediated by A1R.      
  
1-5.2 Ecto-5’-nucleodtidase 
 A key observation that was made during our study of PAP was that there was 
residual AMP histochemical staining in spinal cords and DRGs from Pap-/- animals.  
This suggested that another AMP hydrolyzing enzyme was present in the CNS (See 
Figure 1.6).  We determined that PAP was colocalized with another ectonucleotidase 
called ecto-5’-nucleotidase (NT5E, also known as CD73) (See Figure 1.7).  Though 
other 5’-nucleotidases exist in humans, NT5E is the only enzyme found on the cell 
surface.  Anchored to the membrane by a GPI anchor, this enzyme selectively 
hydrolyzes 5’-monophosphates and shows little affinity for hydrolyzing di- or 
triphosphates (Zimmermann, 1992).   This hydrolytic activity can either be enhanced 
by binding the divalent cations Mg2+ or Zn2+ or reduced by the cations Pb2+ or Hg2+ 
(Fini et al., 1990; Ong et al., 1990).  NT5E also functions best in a pH range of 7-8. 
 Studies by Zimmerman have shown that 5’-AMP is NT5E’s preferred 
substrate (1992).  As such, NT5E is proposed to be a key regulator in purinergic 
signaling in many systems. NT5E has been connected to various physiological 
processes including, epithelial ion transport, permeability of intestinal and vascular 
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tissues, hypoxia, ischemic preconditioning in the heart and kidneys as well as 
inflammation (Colgan et al., 2006).  NT5E has also been connected to lung function, 
renal function and the regulation of immune responses.  These studies reflect the 
near ubiquitous expression of NT5E in many tissues.  Through biochemical and 
histochemical assays, NT5E expression has been detected in the liver, heart, blood 
vessels, lung, colon, kidney, the brain and the spinal cord (Moriwaki et al., 1999; 
Yegutkin, 2008; Zimmermann, 1992, 1996).  Another recent study in our lab has 
confirmed the expression of NT5E in the dorsal horn of the spinal cord as well as the 
DRG (Sowa et al., 2010).  Despite the detection of NT5E in the nervous system, a 
functional role for NT5E in these tissues has yet to be determined. 
 A huge barrier to functional studies of NT5E has been the lack of purified, 
soluble, mammalian NT5E protein (Colgan et al., 2006).  Most studies of NT5E until 
recently have relied on studying the enzyme through cell extracts, lysed tissue and 
tracking the degradation of 5’-AMP to determine the presence and/or activity level of 
mNT5E.  Unfortunately by using these approaches, the possibility remains that other 
enzymes which degrade 5’-AMP are also dephosphorylating the substrate.   To 
address this caveat, many labs have used a 5’nucleotidase protein purified from 
rattlesnake (Crotalus atrox), venom in their studies.  Like NT5E, snake venom 5’-
nucleotidase favors monophosphate substrates, especially AMP, and can bind 
divalent cations (Iwanaga and Suzuki, 1979).  Injections of C. atrox 5’-nucleotidase 
rescued phenotypes in Nt5e-/- mice in three independent studies (Eckle et al., 2007b; 
Hart et al., 2008; Thompson et al., 2004).  Nevertheless, all three studies focused on 
the vascular role of NT5E, not the function of NT5E in the nervous system.  The 
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experiments detailed in this dissertation describe a functional role for NT5E in 
nociception. 
 
1-6 Research Rationale 
 To date, there have been many studies that have established the presence of 
NT5E in the nervous system, yet a physiological role for this enzyme in nervous 
tissues has not been established.  A recently published study by our lab has 
determined that NT5E is localized to small diameter nociceptors in the DRG (Sowa 
et al., 2010).  This study additionally observed that Nt5e-/- mice display more 
sensitivity to nociceptive stimuli— similar to Pap-/- mice.  Injection of AMP into these 
knockout animals also produced a decreased antinociceptive response compared to 
wildtype animals.  This antinociceptive effect did not occur when A1R-/- animals were 
injected with AMP, suggesting that NT5E has a role in processing adenosine for A1R 
receptors.  Though this study established a correlation between NT5E and 
nociception, the exact role of NT5E in nociception could not be confirmed without 
soluble NT5E protein. 
 A previous attempt to generate a recombinant version of secreted rat NT5E 
was attempted by Servos and colleagues in 1998.  Though they successfully 
generated and purified a catalytically active protein, they did not detect the protein in 
the culture medium.  Instead, most of the protein was stuck in the cell pellet used for 
the purification, suggesting that Servos and colleagues failed to completely remove 
the GPI anchor.  Even though this method produced active protein, the difficulty in 
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getting the protein to secrete would likely prevent investigators from collecting 
sufficient amounts of protein to use for in vivo testing. 
 The following dissertation details the generation of a secreted, recombinant 
mouse NT5E protein (mNT5E) and the characterization of that protein using both in 
vitro and in vivo methods.  Our reasons for generating this protein were three-fold: 1) 
to address toxicity concerns associated with introducing an enzyme derived from 
snake venom to the nervous system; 2) to design a vector for a secreted version of 
NT5E that can be easily produced in baculovirus and other organisms used for 
protein purification; 3) to definitively establish NT5E’s participation in nociception.  
Given the role of the ectonucleotidase PAP in nociception, we hypothesized that 
NT5E would also produce long-lasting antinociceptive effects in vivo.  Furthermore 
we predicted that these antinociceptive effects are dependent on A1R.  This 
research could ultimately lead to the development of alternative therapies for 
intractable pain as well as provide a key tool for the study of NT5E in other 
physiological processes. 
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1-7 Figures 
F
igure 1.1 Classification of primary afferent nerves.  The nerves that make up the 
peripheral nervous system have different properties and detect various types of 
stimuli.  (Figure modified from Julius and Basbaum, 2001). (Back to text) 
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Figure 1.2 Model of peripheral and central nociceptive pathways.  Harmful 
stimuli are detected by nociceptors (red line) in the peripheral nervous system and 
carry that information to projection neurons that ascend to the brain through the 
spinal cord (blue line).  The critical synapses in this process are found in the dorsal 
horn.  (Back to text). 
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Figure 1.3 Nociceptive neurons are categorized based on molecular markers.  
Peptidergic neurons (red) express CGRP,  substance P (Sub P) and somatostation 
(somat) and they synapse with neurons in laminae I and II in the dorsal horn of the 
spinal cord.  Nonpeptidergic neurons (green) stain for IB4 and express PAP, 
MrgprD, P2X3 receptors and NT5E.  These neurons project to lamina II.  Lamina II 
middle is a proposed subsection of lamina II inner since the majority of 
nonpeptidergic neurons terminate in this location .  (Figure is modified from Zylka, 
2005). (Back to text) 
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Figure 1.4 Intracellular and extracellular adenosine metabolism.  Inside cells, 
adenosine (ADO) can be generated from three sources: ATP, cAMP or SAH.  
Outside the cell, adenosine either comes from release through equilibrative 
nucleoside transporters (ENT) or catabolism of ATP.  See text for details.  PDE= 
Phosphodiesterase.  (Figure modified from Sawynok and Liu, 2003). (Back to text) 
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 Figure 1.5 PAP Dephosphorlates TMP in nociceptive circuits. (A) HEK 293 cells 
were transfect with a mouse TM-PAP expression construct or (B) an empty 
pcDNA3.1 vector then stained with TMP Histochemistry.  Lumbar DRG (C and D) 
and spinal cord (E and F) from wild-type and Pap-/- mice were stained using TMP 
histochemistry.  6 mM TMP was used as a substrate and the buffer was at pH 5.6 for 
all panels.  Scale bar, 50 µm in A and B, 500 µm in C and D.  Figure from Zylka, et 
al., 2008. (Back to text)
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Figure 1.6 PAP and NT5E dephosphorylate AMP in nociceptive circuits Spinal 
cord (A-F) and DRG tissue (G-I) from wild-type, Pap-/- and Nt5e-/- mice were stained 
using AMP histochemistry.  6 mM AMP and a buffer at pH 7.0 were used for all 
panels.  Scale bar, 500 µm for A-C, 200 µm for D-F, and 50 µm for G-I.  Figure 
modified from Zylka, et al., 2008 and Sowa, et al., 2010. (Back to text). 
 
 
 29 
 
 
 
  
Figure 1.7 PAP and NT5E are colocalized in the Dorsal Horn and DRGs. DRG 
(A-C) and spinal cord (D-F) tissue from adult mice was stained using anti-PAP and 
anti-NT5E antibodies.  Figure was modified from Sowa, et al., 2010. (Back to text)
  
 
 
CHAPTER TWO 
RESEARCH DESIGN AND METHODS 
2-1 Molecular Biology of mNT5E recombinant protein 
The GST-mNT5E-(His)6 baculovirus expression plasmid was generated by 
PCR amplification of nt 131-1696 (from GenBank accession # NM_011851.3) using 
Phusion polymerase and a full-length expression construct of mNT5E as template.  
Primer sequences contained EcoRI sites (underlined) to facilitate cloning into 
pAcSecG2T (BD Biosciences).  N-terminal primer: 5’-
cgcgaattcattgggagctcacgatcctgcacaca.  C-terminal (His)6 tag primer:  5’-
gcggaattcttaatgatgatgatgatgatggaacttgatccgcccttcaacg.   These primers produce a 
product that contains the catalytic domain of mNT5E fused to the (His)6 epitope tag 
but that lacks the signal peptide and GPI anchor sequence (located at Ser523) of 
mNT5E.  The final plasmid was sequence verified. There is only one thrombin 
cleavage site in the coding region of this plasmid, located between the GST tag and 
mNT5E coding sequence (See Figure 2.1).  . 
 
2-2 Purfication of the mNT5E recombinant protein 
The GST-mNT5E-(His)6 plasmid was used to generate recombinant mNT5E 
protein using the BD BaculoGold Expression System (BD Biosciences).  Briefly, we 
infected Hi5 insect cells with high-titer recombinant baculovirus, incubated the cells
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 for 48 hours at 27°C and then removed the cells from  the supernatant by 
centrifugation.  The supernatant containing secreted GST-mNT5E-(His)6 was filtered 
(0.45 µm pore size, Millipore) and concentrated using a Millipore cartridge with a 10k 
retention cutoff.  During concentration, the buffer was exchanged for PBS (10 mM 
sodium phosphate, 140 mM NaCl, pH 7.4).  The concentrated supernatant was 
loaded onto a 5 mL GSTrap FF column (GE Healthcare) using a peristaltic pump at 
4°C.  Loading was performed overnight at a slow flow rate (0.4 mL/min. for 14-16 
hours) to optimize binding of the GST-tagged protein.  The column was then washed 
with 50 mL PBS.  Purified thrombin (GE Healthcare, Cat. # 27-0846-01) was added 
to 2 mL of PBS (250 U thrombin/L of expression culture) and loaded onto the 
GSTrap column using a syringe.  On-column cleavage was allowed to take place for 
16 hours at room temperature.  The pre-loaded GSTrap column was then attached 
to an ÄKTA Explorer chromatography system with UV monitoring.  Cleaved mNT5E 
and thrombin were eluted with PBS (the GST tag remained bound to the column).  
Fractions were monitored with SDS-PAGE to estimate purity, mNT5E concentration 
and cleavage efficiency (which was ~80%).  The cleaved mNT5E was separated 
from thrombin using a Superdex75 10/300 GL column attached to the ÄKTA 
Explorer system.  Proteins were eluted in PBS at a flow rate of 0.5 mL/min.  A 
maximum of 500 µL was injected per run.  Fractions containing cleaved mNT5E 
were pooled, concentrated and then dialyzed against 0.9% saline.  Protein purity 
was confirmed by SDS-PAGE, staining for total protein with GelCode Blue 
(Pierce/Thermo Scientific, Cat. # 24590) and western blotting with anti-NT5E 
antibody (R&D Systems, AF4488).  Amersham full-range rainbow molecular weight 
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markers (GE Healthcare) were used for SDS-PAGE and western blots.  Although 
mNT5E could bind to a nickel chelate column via the (His)6 epitope tag and be 
eluted with imidazole, we found this additional affinity purification step was 
unnecessary.  Recombinant mNT5E was kept at 4°C for short- term (1-2 months) use 
and at -80°C for long-term storage. 
 
2-3 Enzymatic Assays of mNT5E 
Enzymatic reactions (50 µL final) were carried out with recombinant mNT5E 
at 37°C for 3 minutes in 100 mM HEPES, pH 7.0, 4 mM MgCl2 with adenosine 5’-
monophosphate (AMP disodium salt, Fluka, 01930) as substrate.  Reactions were 
stopped by adding 950 µL of the malachite green color reagent [0.03% (w/v) 
malachite green oxalate, 0.2% (w/v) sodium molybdate, 0.05% (v/v) Triton X-100, 
dissolved in 0.7 M HCl] then incubated at room temperature for 30 minutes.  
Inorganic phosphate was quantified by measuring OD650 and comparing to an 
inorganic phosphate (KH2PO4) standard curve (Lanzetta et al., 1979).  Unit (U) 
definition: 1 U hydrolyzes 1 nmol of AMP per minute at 37°C at pH 7.0.  α,β-me-ADP 
was purchased from Sigma (M3763). 
 
2-4 Behavioral Testing of mNT5E 
All behavioral experiments involving vertebrate animals were approved by the 
Institutional Animal Care and Use Committee at the University of North Carolina at 
Chapel Hill.  C57BL/6 mice, 2-4 months old, were purchased from Jackson 
Laboratories.  A1R-/- mice were backcrossed to C57BL/6J mice for 12 generations 
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(Hua et al., 2007; Johansson et al., 2001).  Male mice were used for all behavioral 
studies and were acclimated to the testing room, equipment and experimenter for at 
least three days before testing.  To further reduce variability in behavioral studies, 
mice were almost exclusively tested when in the resting or light sleep behavioral 
state (Callahan et al., 2008).  The experimenter was blind to genotype during 
behavioral testing.   
Thermal sensitivity was measured by heating one hindpaw with a Plantar Test 
apparatus (IITC) following the Hargreaves method (Hargreaves et al., 1988).  The 
radiant heat source intensity was calibrated so that a paw withdrawal reflex was 
evoked in ~10 s., on average, in wild-type C57BL/6 mice.  Cutoff time was 20 s.  
One measurement was taken from each paw per time point to determine paw 
withdrawal latency (See Figure 2.2 A,B).  Mechanical sensitivity was measured 
using semi-flexible tips attached to an Electronic von Frey apparatus (IITC) as 
described elsewhere (Cunha et al., 2004; Inoue et al., 2004).  The force values 
obtained with this apparatus are higher than the force values obtained using 
calibrated von Frey filaments (Inoue et al., 2004) (See Figure 2.2 C,D).  Three 
measurements were taken from each paw then averaged to determine paw 
withdrawal threshold in grams.  To induce inflammatory pain, 20 µL Complete 
Freunds Adjuvant (CFA, from MP Biomedicals) was injected into one hindpaw, 
centrally beneath glabrous skin, with a 30G needle.  We performed spared nerve 
injury surgeries as described by Shields and colleagues (Shields et al., 2003b).  
mNT5E protein was diluted in 0.9% saline for intrathecal injection (5 µL / mouse) 
using the direct lumbar puncture method (Fairbanks, 2003) (See Figure 2.2 E,F).  
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None of the mNT5E-injected mice displayed reduced mobility or paralysis following 
injection, as assessed by visually observing motor activity following injections. 
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2-5 Figures 
 
Figure 2.1 Vector map of the mNT5E plasmid.  The catalytic domain of mNT5E, 
which lacks the signal peptide and GPI anchor sequence (located at Ser523) of 
mNT5E, was fused to a (His)6 epitope tag and inserted into the baculovirus vector 
pAcSecG2T using EcoRI restriction sites.   (Back to text) 
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Figure 2.2 Behavioral techniques for testing nociception. To test thermal 
sensitivity, animals were placed in a Hargreaves apparatus (A) and their paws were 
heated with a radiant heat source (B).  To test mechanical sensitivity, animals were 
 37 
 
placed in individual plastic boxes on a raised wire mesh screen (C) and their paws 
were stimulated through the wire with semi-flexible tips on an Electronic Von Frey 
device (D).  For many of our experiments, animals were injected intrathecally.  To 
accomplish this, an unanestitized mouse would be restrained by the hips with the 
fron half of the animal covered by a towel (E). Then a 30 guage ½ inch needle 
attached to a Hamilton syringe was slipped between the lumbar vertebrate (F).  The 
drug was delivered when the animal’s tail “flicked”, which indicates successful 
puncture of the dura.  (Back to text) 
  
 
 
 
CHAPTER THREE 
RESULTS 
 
3-1 Purification of secreted mouse NT5E using the baculovirus expression 
system 
Mature NT5E is anchored to the membrane via a GPI linkage on Ser523 
(Ogata et al., 1990).  In an effort to generate and purify a secretory (non-membrane 
anchored) version of NT5E, Servos and colleagues generated a baculovirus 
expression construct that contained rat NT5E fused to the signal peptide of gp67 
and that reportedly lacked the GPI-anchor at Ser523 (Jörg Servos et al., 1998).  
While Servos and colleagues successfully generated and purified catalytically active 
rat NT5E, they did not detect NT5E in the tissue culture medium as would be 
expected for a secreted protein.  Instead, NT5E was only present in cell lysates.  
Since we were interested in purifying a secretory version of mouse NT5E (mNT5E) 
from the culture medium, we carefully re-examined the cloning strategy used by 
Servos and colleagues.  We noticed that their C-terminal PCR primer actually 
included Ser523 but excluded the near adjacent Ser526.  Using GPI prediction 
software (Eisenhaber et al., 1999), we confirmed that Ser523 (but not Ser526) was 
the most likely GPI anchor site. 
Since inclusion of this GPI anchor sequence could explain why Servos and 
colleagues were unable to detect NT5E in the culture medium, we generated a new
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 expression construct that was virtually identical to the one used by Servos and 
colleagues except that our construct contained mouse NT5E (Trp29-Phe522; not rat 
NT5E) that was truncated just before Ser523 (See Figure 3.1A).  Our construct also 
contained the gp67 signal peptide, Glutathione S-transferase (GST), a thrombin 
cleavage site to permit removal of GST and a C-terminal hexahistidine (His)6 tag.   
Two days after infecting Hi5 insect cells with recombinant baculovirus we 
detected GST-mNT5E protein in the tissue culture supernatant at approximately 10 
mg/L.  This observation suggested that exclusion of Ser523 was important for 
producing a secreted version of NT5E.  Additionally, based on SDS-PAGE and 
western blotting, the GST-mNT5E found in the medium was largely intact whereas 
crude cell lysates contained truncated as well as intact versions of mNT5E (data not 
shown).  We next purified mNT5E from the culture supernatant in two steps (see 
Methods).  We reasoned that GST, a protein that binds glutathione, might interfere 
with physiological or behavioral studies if administered in vivo.  So as part of this 
purification, we removed GST by cleavage with thrombin.  We confirmed that this 
cleaved mNT5E protein was pure by staining a SDS-PAGE gel for total protein (See 
Figure 3.1B) and western blotting with an anti-NT5E antibody (See Figure 3.1C).  
We observed one predominant band at ~62 kDa, corresponding to the calculated 
molecular weight of unglycosylated mNT5E with a (His)6 tag (61.7 kDa).  No 
additional bands were observed, indicating that mNT5E protein lacked the GST tag 
and was intact.   
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3-2 mNT5E is catalytically active 
We next used enzyme assays to confirm that our purified protein was 
catalytically active.  Purified recombinant mNT5E protein dephosphorylated AMP 
with a Km of 26 µM (See Figure 3.2).  This Km value is within the range of 1-50 µM 
reported by others using AMP as substrate (Hunsucker et al., 2005; Jörg Servos et 
al., 1998).  Recombinant mNT5E was also inhibited by α,β-methylene-adenosine 5’-
diphosphate (α,β-me-ADP; IC50=0.43 µM; See Figure 3.3), a commonly used 
inhibitor of NT5E (Zimmermann, 1992).  For comparison, we found that α,β-me-ADP 
(0.01-500 µM) did not inhibit recombinant mPAP when AMP was used as substrate 
(See Figure 3.4).  Production of recombinant mPAP was described previously (Sowa 
et al., 2009).  These results suggest α,β-me-ADP has selectivity for NT5E over PAP 
—an AMP ectonucleotidase that bears no sequence similarity to NT5E. 
 
3-3 mNT5E is Antinociceptive in Naïve Mice  
We previously found that a single intrathecal injection of PAP had 
antinociceptive, antihyperalgesic and antiallodynic effects that lasted for three days 
and that were dependent on A1R activation (Sowa et al., 2009; Zylka et al., 2008).  
To identify an effective dose of mNT5E for in vivo studies and to determine if mNT5E 
also had long-lasting antinociceptive effects, we intrathecally (i.t.) injected wild-type 
mice with three doses of recombinant mNT5E protein (See Figure 3.5).  We then 
measured noxious thermal and mechanical sensitivity before (baseline, BL) and after 
mNT5E injection.  Six hours after i.t. injection, paw withdrawal latency to the noxious 
thermal stimulus was significantly increased relative to controls and remained 
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elevated for two days at all doses tested (See Figure 3.5A).  mNT5E did not alter 
mechanical sensitivity (See Figure 3.5B) nor did it cause paralysis or sedation at any 
of the doses tested.  We similarly found that PAP (from human, cow and mouse) had 
selective thermal but not mechanical antinociceptive effects in naïve mice and had 
no obvious motor side effects (Sowa et al., 2009; Zylka et al., 2008). 
 
3-3 mNT5E has long-lasting antinociceptive effects that are A1R dependent 
We next evaluated the antinociceptive effects of mNT5E in the CFA model of 
inflammatory pain and the SNI model of neuropathic pain.  We used wild-type (WT) 
and A1R-/- mice to evaluate dependence on A1R activation and used the contralateral 
(non-inflamed/non-injured) paw as control.  As seen previously by us and others 
(Sowa et al., 2010; Wu et al., 2005; Zylka et al., 2008), A1R-/- mice displayed 
enhanced thermal hyperalgesia after CFA injection and after nerve injury relative to 
WT mice (See Figure 3.6 A,C).  In both chronic pain models, a single i.t. injection of 
mNT5E had long-lasting thermal antihyperalgesic and mechanical antiallodynic 
effects in the inflamed/injured paw of WT mice but not A1R-/- mice (See Figure 3.6A-
D).  In the CFA model these antinociceptive effects persisted for two days (See 
Figure 3.6 A,B) whereas in the nerve injury model they persisted for three days (See 
Figure 3.6 C,D).  Consistent with our dose-response study above, mNT5E had 
thermal but not mechanical antinociceptive effects in the control (non-inflamed/non-
injured) paws of WT mice.  mNT5E had no antinociceptive effects in A1R-/- mice, 
highlighting a critical dependence on A1R activation.  When combined with our 
biochemical studies and numerous studies of NT5E by others (reviewed by (Colgan 
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et al., 2006)), our data suggest that all the antinociceptive effects of mNT5E are due 
to production of adenosine and activation of A1R (See Figure 3.7).  The adenosine 
made by NT5E (following i.t. injection) could inhibit nociception by acting upon A1R 
found on DRG neurons and/or spinal neurons (Reppert et al., 1991; Schulte et al., 
2003).  Lastly, the fact that NT5E has pronounced antinociceptive effects in live 
animals places our findings in the most physiologically-relevant context possible. 
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3-5 Figures 
 
Figure 3.1 Purification of recombinant mNT5E.  (A) Diagram of the GST-mNT5E 
expression construct.  (Top) Native mNT5E contains an N-terminal signal peptide 
(ss-cleavage) and GPI anchor site.  (Bottom) The GST-mNT5E fusion construct 
contains the signal peptide from gp67 of baculovirus Autographica californica, GST, 
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a thrombin cleavage site, the catalytic domain of mNT5E and (His)6 tag.  Translation 
start and stop codons are indicated.  (B) GelCode blue-stained SDS-PAGE gel and 
(C) western blot of purified recombinant mNT5E protein (0.05 µg).  The western blot 
was probed with an anti-mNT5E antibody.  (Back to text) 
 
 
 
 
 
 45 
 
 
0 200 400 600 800
0.0
0.5
1.0
1.5
2.0
2.5
AMP Concentration (µM)
n
m
o
l p
ho
sp
ha
te
 
m
in
-
1
 
Figure 3.2  mNT5E dephosphorylates AMP.  Plot of initial velocity at the indicated 
concentrations of AMP at pH 7.0.  Reactions (n=3 per point) were stopped after 3 
min.  Inorganic phosphate was measured using malachite green.  All data are 
presented as means ± s.e.m.  GraphPad Prism 5.0 was used to generate curve. 
(Back to text) 
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Figure 3.3  Inhibition of mNT5E by α,β-me-ADP.  The indicated concentrations of 
α,β-me-ADP were added to reactions (n=3 per concentration) containing mNT5E 
(0.07 µg/µL), 100 mM HEPES, pH 7.0 and 400 µM AMP.  All data are presented as 
means ± s.e.m.  GraphPad Prism 5.0 was used to generate curve.  Error bars are 
obscured due to their small size. (Back to text) 
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Figure 3.4 mPAP is not inhibited by α,β-me-ADP The indicated concentrations of 
α,β-me-ADP were added to reactions (n=3 per concentration) containing mNT5E 
(0.07 µg/µL) or mPAP (0.26 µg/µL), 100 mM HEPES, pH 7.0 and 400 µM AMP.  All 
data are presented as means ± s.e.m.  GraphPad Prism 5.0 was used to generate 
curve.  Error bars are obscured due to their small size. (Back to text) 
 48 
 
 
 
 
Figure 3.5  Dose-dependent antinociceptive effects of intrathecal mNT5E.  
Effects of the indicated amounts of mNT5E on (A) paw withdrawal latency to a 
radiant heat source and (B) paw withdrawal threshold (electronic von Frey 
apparatus).  BL=Baseline.  Injection (i.t.) volume was 5 µL.  n=10 wild-type mice 
were used per dose.  Paired t-tests were used to compare responses between BL 
values and later time points for each group.  * P < 0.05, ** P < 0.005; *** P < 0.0005.  
All data are presented as means ± s.e.m. (Back to text) 
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Figure 3.6  mNT5E has antihyperalgesic and antiallodynic effects in WT mice 
following inflammation and nerve injury.  Wild-type (WT) and A1R-/- mice were 
tested for (A, C) noxious thermal and (B, D) mechanical sensitivity before (baseline, 
BL) and after injection of CFA into one hindpaw (A, B; arrow) or following nerve 
injury (C, D; SNI, arrow).  (A, B) One or (C, D) six days later, mNT5E protein (1.7 U) 
was injected i.t. into all mice (arrowhead) then thermal and mechanical sensitivity 
was measured for several days.  Inflamed/injured and non-inflamed/non-injured 
(control) hindpaws were tested.  Paired t tests were used to compare responses at 
each time point between genotypes (n = 10 animals per genotype).  *P < 0.05, **P < 
0.005, ***P < 0.0005.  All data are presented as means ± s.e.m. (Back to text)
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Figure 3.7 mNT5E protein modulates nociception through activation of A1R 
receptors.  NT5E dephosphorylates AMP in the extracellular space of nociceptive 
neurons which subsequently leads to the activation of antinociceptive A1R.  Further 
study is required to determine the mechanism occurring downstream of A1R 
activation. (Back to text) 
  
 
 
 
CHAPTER FOUR 
DISCUSSION 
 
4-1 NT5E has a Key Role in Nociceptive Circuits 
 An intriguing dichotomy exists in nociceptive purinergic signaling; purinergic 
receptors that are activated by nucleotides are associated with increased 
nociception while receptors that are activated by nucleosides reduce nociception.  
Pronociceptive receptors are likely activated during injury then deactivated as 
antinociceptive receptors work against them.  Eventually, the injury will heal and 
both systems will return to baseline.  However, if there is an imbalance or 
malfunction in either system, pathologies could occur that lead to chronic pain.  
Based on studies in our lab, ectonucleotidases (like NT5E and PAP) serve to restore 
the balance between the two systems by activating the antinociceptive receptor A1R. 
 In our previous study of PAP, there was evidence that other AMP hydrolyzing 
enzymes besides PAP were present in nociceptive circuits.  Subsequently, we found 
that NT5E, a known ectonucleotidase, is extensively colocalized with PAP in both 
the DRG and the spinal cord (Sowa et al., 2010).  This finding suggested that both 
enzymes work in conjunction to dephosphorylate AMP in the extracellular space.  
Following purification of mNT5E, we showed that the protein could dephosphorylate 
AMP similar to the recombinant mPAP generated by our lab for a prior study (Sowa
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 et al., 2009).  Intrathecal injection of mNT5E into naïve mice produced a long-lasting 
antinociceptive effect as well as analgesic effects in two models of chronic pain: the 
CFA model of inflammation and the SNI model of neuropathic pain.  Furthermore, 
we demonstrated that the antinociceptive effects of NT5E are dependent on A1R 
since the antinociceptive effect was abolished in A1R-/- mice. 
 Prior investigations have shown that spinal injection of adenosine alone 
produces temporary antinociceptive effects and only when high doses of adenosine 
are utilized (Belfrage et al., 1999; Sawynok and Sweeney, 1989; Segerdahl et al., 
1995; Segerdahl et al., 1994; Sollevi et al., 1995).  The half-life of adenosine in the 
extracellular space of the spinal cord is very short due to the acute activity of 
nucleoside transporters and metabolic enzymes like adenosine kinase and 
adenosine deaminase which rapidly remove adenosine from the extracellular 
environment (Sawynok and Liu, 2003).  Therefore adenosine is quickly diverted 
away from activating antinociceptive adenosine receptors and analgesia is short-
lived.  Injection of AMP alone has no effect, despite the presence of endogenous 
ectonucleotidases, for a similar reason (Sowa et al., 2010).   Ectonucleotidase-
generated adenosine is likely being metabolized much too quickly to show an 
antinociceptive effect.  By pairing AMP with the adenosine kinase inhibitor ITU, 
thereby increasing the half-life of adenosine, antinociceptive effects were observed 
(Sowa et al., 2010). 
 Use of inhibitors for nucleoside transporters and adenosine metabolic 
enzymes has served to increase the antinociceptive effects of adenosine (Jarvis et 
al., 2002b; Kowaluk and Jarvis, 2000; Lavand'homme and Eisenach, 1999).  Yet 
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none of these inhibitors match the potency or last nearly as long as NT5E or PAP 
protein.  Antinociceptive effects can also be produced with specific agonists for A1R, 
such as CPA (Curros-Criado and Herrero, 2005; Reeve and Dickenson, 1995).  
However, the effects of these agonists are also short-lived.  Additionally, these 
agonists produce profound motor side effects such as paralysis (Zylka et al., 2008).  
These side effects likely occur due to the overt and nonspecific activation of A1R on 
motor neurons as well as nociceptors.  As such, NT5E and PAP provide a means for 
activating A1R without observable side effects in rodents and the endurance of this 
A1R-mediated analgesic effect is most likely due to the remarkably long half-life of 
these enzymes.  Additional studies will have to be conducted to determine the exact 
mechanism behind the enduring analgesia of NT5E and PAP.  Nevertheless, our 
studies have firmly established NT5E as a key regulator of purinergic signaling in 
nociceptive circuits. 
 
4-2 NT5E is well-positioned to modulate adenosine receptors    
 Our study shows that the analgesic and antinociceptive effects of NT5E are 
dependent on A1R.  Overlap between A1R-expressing and NT5E expressing 
neurons occurs in lamina II of the dorsal horn (Schulte et al., 2003).  A1R is 
concentrated near nonpeptidergic terminals in the dorsal horn, but are not in close 
contact with terminals from peptidergic neurons— which project to lamina I.  A1R has 
also been found on the presynaptic terminals of small and medium diameter 
nociceptive neurons (Schulte et al., 2003).  Additionally, multiple groups have found 
that activation of A1R inhibits presynaptic release of glutamate from unmyelinated 
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terminals and also inhibits the activity of postsynaptic neurons in lamina II (Lao et al., 
2001; Li and Perl, 1994; Patel et al., 2001).  Given that NT5E is expressed in the 
nonpeptidergic neurons that are near A1R-expressing neurons, NT5E is in an 
optimal position to interact with these receptors. 
 Another possibility that has yet to be fully tested is the possible interaction of 
NT5E-generated adenosine with other adenosine receptors.  While A2B and A3 
receptors are primarily localized to the periphery, A2AR can be found in DRG 
neurons, glial cells and the spinal cord (Bura et al., 2008; Cunha et al., 2006; Haskó 
et al., 2005; Hussey et al., 2007; Kaelin-Lang et al., 1998).  Debate remains about 
the presence of A2AR in the mouse spinal cord.  One study which utilized 
quantitative audioradiography reported that there was no A2AR in the spinal cord 
(Bailey et al., 2002).  Yet, a more recent study claims that A2AR expression can be 
detected in wild type mice with RT-PCR (Bura et al., 2008).  Nevertheless, due to 
the lack of a specific antibody no study has pinpointed the precise location of A2AR in 
the mouse spinal cord or DRG.  
NT5E most likely does not lead to A2AR activation in vivo.  A recent study 
conducted by Loram, et al. has shown that antinociceptive effects can be achieved 
in rats through intrathecal injection of specific A2AR agonists.  These effects lasted 
for weeks following a single injection and proved to be analgesic in a model of drug-
induced allodynia.  Though this study has yet to be replicated in mice, the fact that 
these effects lasted much longer than effects generated with mNT5E protein 
suggests that A2AR is not being activated by NT5E.  Most likely, NT5E, PAP and 
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A2AR are differentially localized, preventing interaction between the 
ectonucleotidases and A2AR.  Additional in vivo studies with PAP and NT5E in  
A2AR-/- mice have to be conducted to reach a final conclusion. 
 
4-3 Determining the mechanism behind mNT5E antinociception 
 While mNT5E recombinant protein produces antinociceptive effects that are 
similar to PAP in live animals, the mechanism behind mNT5E’s effects has yet to be 
determined beyond A1R (See Figure 3.7).  One approach to determining the 
mechanism would be to develop a cell based assay using culture cells in vitro.  A1R 
activation has been shown to inhibit adenylate cyclase, decrease levels of cAMP, 
decrease PKA activity and also activate PKC (Bhave et al., 2003; Bhave, et al., 
2002; Huang et al., 2006).  Different inhibitors and activators could then be used to 
determine which pathways are being triggered or suppressed by mNT5E.  Additional 
work could be done in vivo if applicable. 
 
4-4 Using mNT5E as a tool for studying adenosine receptor signaling 
 Whereas PAP is expressed primarily in the prostate, the spinal cord and the 
gut, NT5E is found in numerous tissues from macrophages to the lungs 
(Zimmermann, 1992).  This near-ubiquitous expression of NT5E suggests that NT5E 
is intimately connected to adenosine signaling in multiple systems.  Therefore, 
mNT5E protein and its ability to rapidly and specifically deplete AMP could be a 
useful tool for studying the role of adenosine receptor signaling in various 
physiological processes. 
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 Adenosine has been connected to cilia beating frequency in the lungs 
(Lazarowski et al., 2004; Picher et al., 2003; Rollins et al., 2008).  The movement of 
the cilia is essential for clearing mucus from the lungs and a malfunction in cilia 
movement could lead to insufficient defense against infectious lung diseases.  A 
prior study has shown that NT5E as well as alkaline phosphatase is responsible for 
hydrolyzing AMP in lung tissue (Picher et al., 2003).  mNT5E protein could be used 
to definitively show that NT5E is required for regulating cilia movement.  The protein 
might also be potentially useful in future treatments for disorders like Cystic Fibrosis 
where controlling cilia beat frequency might help clear troublesome mucus. 
 mNT5E could also be used to further study the role of purinergic signaling in 
sleep.  Caffeine is a well-known stimulant that antagonizes both A1 and A2A 
adenosine receptors.  Most adults in this country start their days by blocking out 
adenosine with a cup of coffee which is a testament to the importance of adenosine 
in regulating sleep (Basheer et al., 2004).  And given the wide expression of NT5E in 
the brain, it is likely that NT5E is an important player in the regulation of sleep.  
Studies have shown that adenosine levels fluctuate in different parts of the brain 
between consciousness and sleep (Huston et al., 1996; Murillo-Rodriguez et al., 
2004; Porkka-Heiskanen et al., 1997).  Adenosine is also critical for regulating the 
depth of and length of sleep (Landolt, 2008; Porkka-Heiskanen et al., 1997).  
Blocking adenosine metabolism leads to prolonged sleep and more intense non-
REM sleep (Okada et al., 2003; Radek et al., 2004; Radulovacki et al., 1983).  Given 
that sleep studies have yet to be conducted on Nt5e-/- or Pap-/- mice, the role of 
ectonucleotidases in sleep regulation remains unclear.  mNT5E could be a useful 
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tool in sleep studies and may demonstrate therapeutic value for treating sleep 
disorders. 
 In addition to sleep and lung function, adenosine has a part in regulating 
vascular functions pertaining to ischemia.  During stress or injury, the cardiovascular 
system releases adenosine which then acts on receptors to promote cell survival 
(Eltzschig et al., 2003).  Call ischemic preconditioning, this cardioprotective process 
can reduce the size of myocardial infarctions (Eckle et al., 2007b; Headrick et al., 
2003).  Expression of NT5E increases during this process and is the most likely 
source of adenosine production (Eckle et al., 2007a; Headrick et al., 2003; Kitakaze 
et al., 1999).  In vivo studies using snake venom failed to stimulate ischemic 
preconditioning using purified 5’ nucleotidase (Eckle et al., 2007b).  The lack of 
effect may be a species-specific effect.  Therefore it remains possible that mNT5E is 
cardioprotective.  Additionally, the toxicity concerns inherent with using snake venom 
proteins would be eliminated by using recombinant mNT5E. 
 Response to hypoxia is another system that is closely controlled by 
adenosine.  Levels of adenosine rise in the CNS following hypoxia (Koos et al., 
1997).  This increase has been connected to hypoxia-inducible factor-1, a protein 
that mediates upregulation of NT5E (Ledoux et al., 2003; Synnestvedt et al., 2002; 
Thompson et al., 2004).  As such, mNT5E protein could be used to protect against 
hypoxic damage.  A study which used snake venom 5’-nucleotidase showed that the 
protein could reduce vascular permeability in wildtype mice under hypoxic conditions 
thereby reducing the severity of the pulmonary edema that the animals suffered 
(Thompson et al., 2004).  Mammalian NT5E would likely perform just as well or 
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better than the snake venom protein, making mNT5E a useful protein for studying 
the purinergic signaling associated with hypoxia. 
 Adenosine signaling has also been tied to inflammation.  While the role of 
central nervous system A2AR in nociception remains unclear, there is no doubt that 
these receptors have anti-inflammatory properties in immune cells (Sitkovsky et al., 
2004).  Activation of these receptors ultimately leads to the inhibition of cytokine 
production as well as promoting an increase in anti-inflammatory cytokines 
(Erdmann et al., 2005; Jacobson and Gao, 2006; Lappas et al., 2005; Sitkovsky et 
al., 2004).  NT5E, like the A2AR, is expressed extensively in the immune system.  A 
few studies have shown that NT5E-generated adenosine affects inflammation, but 
these studies were dependent on either genetic manipulation or indirect 
measurement methods to reach their conclusions (Cronstein, 2005; Eltzschig et al., 
2004; Morabito et al., 1998).  Therefore, mNT5E protein could be utilized in 
inflammatory studies to determine whether NT5E affects inflammation.  In the future, 
the protein might also be a useful anti-inflammatory agent for treating immune 
disorders and chronic inflammatory conditions like arthritis. 
 
4-5 Exploring the Combined Roles of NT5E and PAP 
 Though our lab has provided evidence that NT5E and PAP are 
antinociceptive ectonucleotidases that function through the A1R, the question of how 
these two enzymes operate together under physiological conditions remains.  
Considering that these two enzymes with similar mechanisms of action are 
 59 
 
extensively colocalized, it is logical to conclude that there is functional redundancy.  
But why would such a redundancy evolve in mammals? 
 One possibility is that the enzymes only function under specific conditions.  
NT5E performs optimally at a neutral pH and exclusively hydrolyzes 5’-
monophosphates, whereas PAP can function well within a pH range of 4-8 and can 
dephosphorylate different substrates (including ADP and ATP, though AMP remains 
the favored substrate) (Silverman and Kruger, 1988a; Van Etten, 1982; 
Zimmermann, 1992).  Additionally the average Km value for AMP is a thousand-fold 
smaller for NT5E than it is for PAP (Sowa et al., 2009; Zimmermann, 1992).  
Therefore NT5E and PAP may be capable of performing the same functions, but 
under different conditions.  In normal conditions with a neutral pH environment, 
NT5E might have a better affinity for AMP than PAP.  Injury or inflammation, 
however, could lead to changes in extracellular pH that decreases NT5E’s affinity for 
AMP.  In this situation, PAP would still be able to function and mediate analgesia 
through A1R until a neutral pH is restored. 
 The dual influence of NT5E and PAP also has yet to be extensively studied in 
the peripheral nervous system.  Our lab has found both PAP and NT5E on 
nociceptive axon terminals in the epidermis as well as cells in the superficial dermis 
and keratinocytes (Sowa et al., 2010; Zylka et al., 2008).  All four adenosine receptor 
subtypes are found in skin keratinocytes, yet it is not known whether NT5E or PAP 
interact with these receptors (Burnstock, 2009).  The fact that all the knockout 
animals for NT5E, PAP and A1R show increased sensitivity to mechanical 
stimulation of their paws following injury indicates that adenosine signaling is 
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important for nociception.  Yet, studies of the peripheral actions of purified PAP and 
NT5E proteins will have to be conducted to determine if these ectonucleotidases are 
capable of promoting analgesia through peripheral nerve endings. 
 
4-6 Ectonucleotidases and the Future of Pain Treatment 
 The discovery of antinociceptive ectonucleotidases in our lab provides 
exciting new possibilities for pain therapy.  Since these enzymes are endogenous to 
the nervous system, they are unlikely to produce toxic side effects and are less likely 
to generate complications with the body’s innate defenses.  An additional benefit of 
treating pain with these enzymes is that no observable side effects, such as 
paralysis, have appeared in our animal studies.  This is potentially a distinct 
advantage over treating pain with adenosine alone as non-specific signaling can 
occur, leading to activation of receptors besides A1R.  The problem of non-specific 
signaling has been noted in clinical trials where adenosine treatment in humans led 
to headaches, back pain and other undesirable side effects (Belfrage et al., 1999; 
Eisenach et al., 2002; Lavand'homme and Eisenach, 1999; Segerdahl et al., 1995; 
Sollevi et al., 1995).  Direct activation of A1R also presents a problem as many 
agonists have motor side effects (Sawynok, 1998; Zylka et al., 2008).  Therefore the 
indirect activation of A1R through these ectonucleotidases presents a multitude of 
potential treatment options. 
 One fairly obvious treatment method would be to inject recombinant NT5E or 
PAP protein into patients.  Since both proteins have been successfully purified, this 
is one of the most feasible approaches for treating patients with intractable pain. The 
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drawback of treating patients with pure protein is that so far our studies have only 
shown that purified PAP and NT5E are effective when injected intrathecally.  This 
delivery method would be beneficial to patients with the most severe debilitating pain 
conditions or could be used to deliver the enzyme for patients undergoing surgery, 
but would not ultimately be practical for most patients who suffer from chronic pain.  
The proteins would be digested if they were delivered orally.  As such, one approach 
would be to search for inhibitors and activators of NT5E and PAP that could possibly 
be delivered orally or through intravenous injection.   
A full study of the side effects of NT5E and PAP in animals also has yet to be 
completed.  Though we have not seen any severe side effects in the animals we 
have tested, there may be more subtle side effects that cannot be detected by 
merely looking at the animals.  Cardiac function and body temperature could be 
measured following PAP or NT5E treatment to determine if there are any adverse 
effects on these systems.  Motor function could also be more thoroughly assessed 
through tests such as the rotorod, the grip test, and gait measurement.  Given the 
importance of adenosine in regulating sleep, treated animals might also be 
examined for any irregularities in their sleep routine.  The effect of these peptides on 
cognition, emotions and concentration cannot be thoroughly assessed through 
animal testing.  Nevertheless, all possible side effects that can be tested in the 
animal model will have to be evaluated. 
An additional issue that remains to be addressed by our studies is the 
effectiveness of our enzymes in female animals.  In humans, a disproportionate 
number of women are reported to suffer from chronic pain conditions compared to 
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men (Foundation, 2009).  Numerous studies have explored this disparity between 
the genders by using animal models and there is a growing body of evidence that 
gonadal hormones affect nociception (Craft et al., 2004).  Despite a recommendation 
by the International Association for Studying Pain that all researchers conduct their 
behavioral tests with both sexes, or only in females if there are budget constraints, 
the majority of pain studies continue to be conducted solely in male animals 
(Greenspan et al., 2007).  Whether gender testing is the responsibility of the primary 
researcher or the companies which prepare treatments for use in humans is still 
open for debate.  Regardless, new insights may be gained by testing the 
effectiveness of NT5E and PAP proteins in female animals. 
A great deal of hard work remains to translate our ectonucleotidase-based 
treatments from rodents to human patients.  In the face of a growing pain epidemic, 
these challenges are worth undertaking.  Pain afflictions are debilitating not only to 
the individuals who endure them, but also inflict great damage, both financial and 
emotional, on our society at large.  Our findings have the potential to provide new 
options to the millions of people nationwide that suffer from chronic pain. 
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APPENDIX I 
 
Acph1: A Catalytically Active Ortholog of PAP in Drosophila melanogaster 
 
Summary 
Our lab has successfully demonstrated that spinal injection of secreted PAP 
produces antinociceptive in mice. Nevertheless, using a mouse model has 
limitations that make it difficult to identify proteins that functionally and genetically 
interact with PAP.  An ortholog of PAP in Drosophila melanogaster, called Acph1 
(dmPAP), which shares sequence and biochemical similarities to mouse and human 
PAP was identified in prior studies (Chung et al., 1996; MacIntyre, 1966).  To 
functionally test dmPAP in vitro, we constructed expression clones of dmPAP fused 
to the yellow fluorescent protein Venus and the red fluorescent protein mCherry.  
dmPAP possessed a similar perinuclear and membrane localization to mouse PAP 
when expressed in cultured Rat1 cells (Figure A1.1).  Histochemical staining in HEK 
293 cells using adenosine monophosphate (AMP) as a substrate also revealed 
staining patterns similar to mouse and human PAP (Figure A1.2).  A fluorometric 
assay and additional histochemical staining showed that dmPAP could be inhibited 
by L(+)-tartrate, a known inhibitor of mammalian PAP (Figure A1.3 and Figure A1.4).  
These results suggested that dmPAP has the same enzymatic properties as the 
mouse and human versions.  However, studies of calcium responses in dmPAP 
transfected cells were inconclusive and  embryonic in situ hybridization of dmPAP in 
wildtype embryos also provided no firm evidence that dmPAP is present in the 
nervous system of Drosophila melanogaster (data not shown and Figure A1.5).  As 
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such we concluded that there were not enough similarities between the fly model 
and our current mouse model to pursue genetic studies in fruit flies. 
Methods 
Molecular Biology of the dmPAP construct 
The dmPAP expression plasmid was generated by PCR amplification of nt 185-1498 
(from GenBank accession # NM_080178.4) using Phusion polymerase and the fly 
cDNA construct RE14694 (DRGC, Indiana University) as a template.    N-terminal 
primer: 5’-cgctctagaaccatgtggaaccacccaagccag  C-terminal primer:  5’-
cgccggccggagccatttgagagtacgagg.  The EagI site in the C terminal primer sequence 
(underlined) was used to link the dmPAP to an expression sequence for the 
fluorescent protein Cherry.  Then Xb I site (underlined) in the N-terminal primer 
sequence and another Xb I site located at the C-terminal end of the mCherry 
sequence were used  to facilitate cloning the dmPAP sequence plus mCherry into 
the vector pcDNA3.1.  The final plasmid contained an expression sequence for 
dmPAP and mCherry and was sequence verified.  
Cell Transfection 
Constructs were transfected into HEK293 cells or Rat1 cells using Lipofectamine 
(18324-012, Invitrogen) and Plus Reagent (11514-015, Invitrogen) according to the 
included protocol.  Cells were incubated in the transfection reagents for at least 
three hours in serum free media then replaced with serum-containing media for 
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overnight incubation.  Expression of fluorescent constructs was confirmed with a 
Zeiss Axioskop. 
Cell Histochemistry 
Enzyme histochemistry was performed essentially as described by Shields 
et al., with modifications suggested by Silverman and Kruger (Shields et al., 2003a; 
Silverman and Kruger, 1988b). Briefly, cells were washed twice with 40 mM Trizma-
Maleate (TM) buffer, pH 5.6, then once with TM buffer containing 8% (w/v) sucrose. 
Samples were then incubated at 37°C for 2 hr in TM b uffer containing 8% sucrose 
(w/v), 1 mM adenosine monophosphate , and 2.4 mM lead nitrate. Lead nitrate was 
made fresh immediately prior to use. To reduce nonspecific background staining, 
samples were washed once with 2% acetic acid for 1 min. Samples were then 
washed three times with TM buffer, developed for 10 s with 1% sodium sulfide, 
washed several times with PBS, pH 7.4, and mounted in Gel/Mount (Biomeda).  
Images were acquired using a Zeiss Axioskop and an Olympus DP-71 camera. 
 
Fluorometric Assay 
Cultured HEK293 cells transfected with dmPAP were lysed using ice cold RIPA 
Lysis Buffer (1% Igepal, 0.5% sodium deoxycholate, 0.1% SDS dissolved in 1X 
PBS).  Protease inhibitors (a single Mini Complete Tablet, 11836153001, Roche) 
were added to the buffer before lysis.  Twenty-five microliters of 100 mM sodium 
acetate (+/-) L(+)-tartrate was added to 25 µL cell lysate along with 50 µL of 200 mM 
DiFMUP substrate (from Enzchek phosphatase assay system, E6646, Invitrogen).  
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Flourescence was measured with excitation set at 390 nm and emission detection at 
510 nm on a Fluorscan Ascent FL plate reader (Thermosystems). 
 
Embryonic In Situ Hybridization 
Fly embryos were collected from grape-juice agarose plates.  Embryos were 
dechorionated for 5 min with a 50% bleach solution then rocked for 25 min in a 50% 
heptane, 5% paraformaldehyde(PFA) in 1X PBS gradient solution to fix the embryos.  
Following fixation, the fixative layer of the solution was removed and methanol was 
added to remove the vitallin membrane.  Embryos were stored in 100% methanol at 
-20°C.  Embryos were rehydrated in a 3:1, methanol: 4% PFA in 1X PBS solution for 
2 min then in a 1:3, methanol: 4% PFA in 1X PBS solution for 5 min.  Afterwards, 
embryos were washed six times with a 0.1% Tween 20, 1X PBS solution.  Then 
embryos were rocked in hybridization buffer (4X SSC, 50% deionized formamide, 
0.01% Tween 20) for 1 hr at room temperature.  In the meantime, an Acph1 anti-
sense probe was diluted 1:100 in hybridization buffer with 5% dextran sulfate.  
Dilution was heated at 85°C for 5 mins, placed on ice f or 2 mins then heated at 55°C 
for 2 mins.  Hybridization buffer was removed from the embryos and replaced with 
the warmed probe.  Embryos were incubated in probe overnight at 55°C.  Next day 
the embryos were washed in wash buffer (2X SSC, 50% formamide, 0.1% Tween 
20) for 30 min intervals eight times.  Then embryos were incubated overnight in 
wash buffer at 55°C.  Next day the embryos were rinsed  in 0.1% Tween 20, 1X PBS 
solution then rocked for 30 min at room temperature in the same solution.  An 
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antibody solution containing 5% goat serum and a 1:2000 dilution of anti-DIG-AP fab 
fragments (Roche) was added to the embryos and embryos were rocked for 2 hr at 
room temperature.  Embryos were rinsed twice with 0.1% Tween 20, 1X PBS 
solution then washed nine times with the same solution at 10 min per wash.  Then 
the embryos were rinsed two times with fresh made AP buffer (50 mM MgCl2, 100 
mM NaCl, 100 mM Tris pH 9.5, 0.01% Tween 20).  Afterwards embryos were treated 
with BCIP/NBT color solution (3.5 µL 50 mg/mL BCIP and 4.5 µL NBT in 1 mL AP 
buffer) until desired color was achieved.  Embryos were washed three times in with 
0.1% Tween 20, 1X PBS solution to stop the color reaction then mounted on slides 
with 70% glycerol. 
Figures 
 
Figure A1.1 dmPAP and mPAP have similar localization in cultured cells.  
Cultured Rat1 cells were transfected with fluorescently tagged constructs for dmPAP 
and mPAP. Fluorescence from both dmPAP constructs appears in the membrane 
and the perinuclear space.  This resembles the fluorescence in mPAP transfected 
cells, thereby suggesting a similar localization of mPAP and dmPAP. 
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Figure A1.2 dmPAP dephosphorylates AMP.  Cultured HEK 293 cells were 
transfected either with fEGFP, a cherry tagged dmPAP construct or a cherry tagged 
mPAP construct.  Lead histochemistry was performed at pH 5.6 using 1 mM 
adenosine monophosphate (AMP) as a substrate.  Cells transfected with dmPAP 
had near identical staining patterns to mPAP.  
Figure A1.3 dmPAP is inhibited by L(+) Tartrate.  HEK 293 cells were transfected 
with dmPAP and lysed using RIPA lysis buffer.  Cell lysates were tested (w/ and w/o) 
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tartrate in a fluorometric assay for acid phosphatase activity using DiFMUP as a 
substrate.  Activity was reduced by half when lysates were treated with tartrate.    
Figure A1.4 dmPAP dephosphorylation of AMP is inhibited by L(+) tartrate.  
HEK293 cells were transfected with either fEGFP or dmPAP.  Lead histochemistry 
was performed (w/ and w/o) tartrate at pH 5.6 using 1 mM AMP as a substrate.  
AMP staining pattern was eliminated in tartrate treated cells, suggesting that tartrate 
inhibited dmPAP dephosphorylation of AMP.  
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 Figure A1.5 dmPAP has analogous expression to mPAP in D. melanogaster 
embryos aside from the CNS.  In-situ hybridization of wildtype fly embryos for 
dmPAP revealed expression in (A) the epidermis, (B) the salivary glands, and (C) 
the gut.  Staining was either absent or undetectable in the CNS (D).  PAP is also 
expressed in skin, salivary glands, and the gut in mammals, yet the lack of 
prominent CNS staining led us to determine that the fly model would not be useful 
for conducting genetic studies that involve nociception.
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APPENDIX II 
 
PAP is Capable of Dephosphorylating Benfotiamine 
Summary 
 Research has shown that B vitamins, especially thiamine, are required for 
proper nervous system function (Itokawa, 1996).  Deficiencies in thiamine lead to a 
condition called Beriberi which is characterized by fatigue, loss of motor function and 
widespread chronic pain (Lonsdale, 2006).  On the other hand, thiamine treatment 
has been shown to be analgesic in animal models of pain (Caram-Salas et al., 2006; 
França et al., 2001; Jolivalt et al., 2009; Song et al., 2009).  High doses of thiamine, 
however, are required to see this effect.  Prior investigators proposed that the water 
solubility of thiamine leads to a small rate of absorption.  As such, benfotiamine, a 
lipid-soluble derivative of thiamine was synthesized in the early 1960s.  Benfotiamine 
has been shown to be analgesic in models of neuropathic pain and inflammatory 
pain in both humans and rodents (Jolivalt et al., 2009; Sánchez-Ramírez et al., 
2006; Simeonov et al., 1997; Stracke et al., 1996).  Furthermore, our lab has shown 
that when benfotiamine is antinociceptive when injected into naïve animals 
(Coleman, et al., unpublished data).   Currently, the mechanism behind 
benfotiamine’s analgesic effects is unknown.  Our lab has recently discovered that 
benfotiamine antinociceptive effects are ablated in Pap-/- mice.  These data suggest 
that PAP is a key factor in the antinociceptive effects of benfotiamine.  Here we 
show that PAP has the capability to dephosphorylate benfotiamine in two separate 
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assays (Figure A2.1 and Figure A2.2).  Additionally, we show that PAP has a better 
affinity for dephosphorylating benfotiamine in an acidic environment than a generic 
alkaline phosphatase—another class of ectonucleotidases found in the spinal cord 
(Figure A2.3 and Table A2.1).  These findings confirm that PAP is capable of 
dephosphorylating benfotiamine in vitro. 
  
Methods 
Enzymatic reactions (50 µL final) were carried out with recombinant mNT5E at 37°C 
for 3 minutes in 100 mM sodium acetate for the pH 5.6 reactions, 100 mM HEPES 
for the pH 7.0 reactions, and 100 mM Tris for pH 8.5 reactions
 
with adenosine 5’-
monophosphate (AMP disodium salt, Fluka, 01930) as substrate.  Reactions were 
stopped by adding 950 µL of the malachite green color reagent [0.03% (w/v) 
malachite green oxalate, 0.2% (w/v) sodium molybdate, 0.05% (v/v) Triton X-100, 
dissolved in 0.7 M HCl] then incubated at room temperature for 30 minutes.  
Inorganic phosphate was quantified by measuring OD650 and comparing to an 
inorganic phosphate (KH2PO4) standard curve (Lanzetta et al., 1979). Human PAP 
(Sigma,P1774, 100 U/ml) was dialyzed against 0.9% saline using Slide-A-Lyzer Mini 
dialysis units (Pierce, 69576) for 4 hr at 4 °C then d iluted in 0.9% saline to a 
concentration of 0.43 µg/µL (0.02 U/ µL).  Recombinant bovine alkaline phosphatase 
was purchased from Sigma (P8361, expressed in Pichia pastoris, >4000 U/mg 
protein) and was diluted to 2.1 µg/µL in 0.9% saline (0.5 U/ µL).  One microliter of 
enzyme was used for each reaction. 
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Figure A2.1 Human PAP dephosphorylates Benfotiamine in a malachite green 
assay.  Plot of initial velocity at the indicated concentrations of TMP or benfotiamine 
at (A) pH 5.6 and (B) pH 7.0.  Km values at pH 5.6 are 354.4 µM and 101.6 µM for 
TMP and benfotiamine respectively.  Km values at pH 7.0 are 1361 µM and 1865 µM 
respectively. Reactions (n=3 per point) were stopped after 3 min.  Inorganic 
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phosphate was measured using malachite green.  All data are presented as means 
± s.e.m.  GraphPad Prism 5.0 was used to generate curves. 
 
  
Figure A2.2 Human PAP Dephosphorylates Benfotiamine in a lead 
histochemistry assay.  Cultured HEK 293 cells were transfected either with (A) 
fEGFP, (B, C) a cherry tagged transmembrane mPAP construct or (D) a secreted 
mPAP construct.  Lead histochemistry was performed at pH 5.6 using (B only) 6 mM 
TMP as a substrate or (A, C, D) 6 mM Benfotiamine.  Cells transfected with mPAP 
and secreted PAP showed staining patterns that indicate dephosphorylation of the 
substrate. 
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Figure A2.3 Bovine alkaline phosphatase dephosphorylates Benfotiamine.  
Plot of initial velocity at the indicated concentrations of AMP or benfotiamine at (A) 
pH 8.5, (B) pH 7.0 and (C) pH 5.6.  Km values are 731.3 µM and 64.6 µM at pH 8.5, 
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686.4 µM and 471.4 µM at pH 7.0, and 424.5 µM and 255.7 µM at pH 5.6 for AMP 
and benfotiamine respectively.  Reactions (n=3 per point) were stopped after 3 min.  
Inorganic phosphate was measured using malachite green.  All data are presented 
as means ± s.e.m.  GraphPad Prism 5.0 was used to generate curves. 
 
 
Table A2.1 Km values (µM) for PAP at different pH values 
 
Substrate      AMP    Benfotiamine     TMP 
 
pH  5.6 7.0  5.6 7.0 8.5  5.6 7.0 
 
PAP  447.9 512.3  101.6 1865   -  354.4 1361 
 
ALP  424.5 686.4  255.7 471.4 64.6    -     -
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